Office: 208 Salk Pavilion, 335 Sutherland drive, Pittsburgh PA 15261

Phone: 412-624-4683

Fax: (412) 624-1850

Email: nolin@pitt.edu

orcidpubmedLinkedIn

Thomas D. Nolin, PharmD, PhD is a tenured Associate Professor in the Department of Pharmacy & Therapeutics, and in the Department of Medicine Renal-Electrolyte Division at the University of Pittsburgh. He is an NIH funded investigator whose primary research focuses on developing an understanding of the impact of kidney disease and renal replacement therapy (RRT) on nonrenal metabolism and transport pathways and corresponding effects on drug exposure and response. Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of clinical-translational studies exploring pharmacokinetics/pharmacodynamics and consequent drug dosing requirements in patients with kidney disease. He served as chair of the Kidney Health Initiative workgroup to assess pharmacokinetics during RRT and as co-chair of the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup. Dr. Nolin has published over 125 manuscripts and book chapters and has presented more than 140 scientific abstracts and invited talks. He serves on the editorial board of the Clinical Journal of the American Society of Nephrology, and as an Editor of the textbook Pharmacotherapy: A Pathophysiological Approach. Dr. Nolin is a Fellow of the American College of Clinical Pharmacy, the American College of Clinical Pharmacology, and of the American Society of Nephrology.

The research focus of the Nolin laboratory includes characterizing the impact of kidney disease and renal replacement therapy on drug exposure (clinical pharmacokinetics) and response (pharmacodynamics), evaluating the functional expression of drug metabolizing enzymes and transporters, and developing novel quantitative analytical techniques. My primary research focuses on studying the effect of kidney disease on pathways of nonrenal drug clearance, particularly those mediated by drug metabolizing enzymes and active transporters. The long-range goal of our research is to identify the mechanisms by which kidney disease contributes to alterations in these drug elimination pathways, to understand the impact of these alterations on drug response and patient outcomes, and ultimately, to use this information in the development of strategies to optimize drug use in patients with kidney disease.

SELECTED PEER REVIEWED PUBLICATIONS (2015-2019)

Crisamore KR, Nolin TD, Coons JC, Empey PE. Engaging and Empowering Stakeholders to Advance Pharmacogenomics. Clin Pharmacol Ther. 2019 Jun 26;. doi: 10.1002/cpt.1470. [Epub ahead of print] PubMed PMID: 31241758.

Prokopienko AJ, West RE 3rd, Stubbs JR, Nolin TD. Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease. J Pharm Biomed Anal. 2019 Jun 24;174:618-624. doi: 10.1016/j.jpba.2019.06.033. [Epub ahead of print] PubMed PMID: 31276982; PubMed Central PMCID: PMC6677161.

Hoffman RS, Juurlink DN, Ghannoum M, Nolin TD, Lavergne V, Gosselin S. Extracorporeal treatment in salicylate poisoning. Clin Toxicol (Phila). 2019 May;57(5):377-378. doi: 10.1080/15563650.2018.1517882. Epub 2018 Oct 11. PubMed PMID: 30307333.

Casal MA, Nolin TD, Beumer JH. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. Clin J Am Soc Nephrol. 2019 Apr 5;14(4):587-595. doi: 10.2215/CJN.11721018. Epub 2019 Mar 19. PubMed PMID: 30890575; PubMed Central PMCID: PMC6450339.

Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates. Clin Pharmacol Ther. 2019 Mar;105(3):719-729. doi: 10.1002/cpt.1205. Epub 2018 Oct 26. PubMed PMID: 30074626.

Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE 3rd, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD. Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with End-stage Kidney Disease Receiving Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2019 Jan 21;. doi: 10.2215/CJN.06190518. [Epub ahead of print] PubMed PMID: 30665924; PubMed Central PMCID: PMC6390920.

Ramezani A, Nolin TD, Barrows IR, Serrano MG, Buck GA, Regunathan-Shenk R, West RE 3rd, Latham PS, Amdur R, Raj DS. Gut Colonization with Methanogenic Archaea Lowers Plasma Trimethylamine N-oxide Concentrations in Apolipoprotein e-/- Mice. Sci Rep. 2018 Oct 3;8(1):14752. doi: 10.1038/s41598-018-33018-5. PubMed PMID: 30283097; PubMed Central PMCID: PMC6170401.

Ghannoum M, Hoffman RS, Gosselin S, Nolin TD, Lavergne V, Roberts DM. Use of extracorporeal treatments in the management of poisonings. Kidney Int. 2018 Oct;94(4):682-688. doi: 10.1016/j.kint.2018.03.026. Epub 2018 Jun 27. Review. PubMed PMID: 29958694.

Johnson C, Prokopienko AJ, West RE 3rd, Nolin TD, Stubbs JR. Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice. Drug Metab Dispos. 2018 Sep;46(9):1304-1309. doi: 10.1124/dmd.118.081646. Epub 2018 Jun 18. PubMed PMID: 29915157.

Nolin TD, Perazella MA. Introduction to Nephropharmacology for the Clinician: A New CJASN Series. Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1083-1084. doi: 10.2215/CJN.03180318. Epub 2018 Apr 16. PubMed PMID: 29661769; PubMed Central PMCID: PMC6032583.

Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC, Wanner C. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018 Jun 21;39(24):2314-2325. doi: 10.1093/eurheartj/ehy060. PubMed PMID: 29522134; PubMed Central PMCID: PMC6012907.

Roumelioti ME, Trietley G, Nolin TD, Ng YH, Xu Z, Alaini A, Figueroa R, Unruh ML, Argyropoulos CP. Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: a meta-analysis of published studies. Nephrol Dial Transplant. 2018 Jun 1;33(6):1025-1039. doi: 10.1093/ndt/gfx311. PubMed PMID: 29186592.

Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018 May;103(5):854-867. doi: 10.1002/cpt.807. Epub 2017 Oct 9. PubMed PMID: 28990182; PubMed Central PMCID: PMC5947523.

Choi YJ, Zhou D, Barbosa ACS, Niu Y, Guan X, Xu M, Ren S, Nolin TD, Liu Y, Xie W. Activation of Constitutive Androstane Receptor Ameliorates Renal Ischemia-Reperfusion-Induced Kidney and Liver Injury. Mol Pharmacol. 2018 Mar;93(3):239-250. doi: 10.1124/mol.117.111146. Epub 2018 Jan 19. PubMed PMID: 29351922; PubMed Central PMCID: PMC5801556.

Hudson JQ, Nolin TD. Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning. Adv Chronic Kidney Dis. 2018 Jan;25(1):14-20. doi: 10.1053/j.ackd.2017.10.003. Review. PubMed PMID: 29499882.

Prokopienko AJ, Nolin TD. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. Expert Rev Clin Pharmacol. 2018 Jan;11(1):71-82. doi: 10.1080/17512433.2018.1378095. Epub 2017 Sep 20. Review. PubMed PMID: 28905671; PubMed Central PMCID: PMC5979269.

Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney Int Rep. 2017 Nov;2(6):1050-1058. doi: 10.1016/j.ekir.2017.06.002. eCollection 2017 Nov. PubMed PMID: 29270514; PubMed Central PMCID: PMC5733827.

Clark RSB, Empey PE, Bayır H, Rosario BL, Poloyac SM, Kochanek PM, Nolin TD, Au AK, Horvat CM, Wisniewski SR, Bell MJ. Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. PLoS One. 2017;12(7):e0180280. doi: 10.1371/journal.pone.0180280. eCollection 2017. PubMed PMID: 28686657; PubMed Central PMCID: PMC5501440.

Hagos FT, Daood MJ, Ocque JA, Nolin TD, Bayir H, Poloyac SM, Kochanek PM, Clark RS, Empey PE. Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine. Xenobiotica. 2017 Apr;47(4):346-353. doi: 10.1080/00498254.2016.1187777. Epub 2016 Jun 9. PubMed PMID: 27278858; PubMed Central PMCID: PMC5572076.

Nolin TD. Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud. Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2101-2103. doi: 10.2215/CJN.11011016. Epub 2016 Nov 28. PubMed PMID: 27895133; PubMed Central PMCID: PMC5142077.

Vijayan A, Faubel S, Askenazi DJ, Cerda J, Fissell WH, Heung M, Humphreys BD, Koyner JL, Liu KD, Mour G, Nolin TD, Bihorac A. Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment. Am J Kidney Dis. 2016 Jul;68(1):19-28. doi: 10.1053/j.ajkd.2015.12.033. Epub 2016 Mar 4. PubMed PMID: 26948834; PubMed Central PMCID: PMC4921267.

Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clin Pharmacol Ther. 2016 Jul;100(1):75-87. doi: 10.1002/cpt.337. Epub 2016 Mar 7. PubMed PMID: 26800425; PubMed Central PMCID: PMC5024330.

Roumelioti ME, Nolin T, Unruh ML, Argyropoulos C. Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico. PLoS One. 2016;11(4):e0153157. doi: 10.1371/journal.pone.0153157. eCollection 2016. Review. PubMed PMID: 27055286; PubMed Central PMCID: PMC4824495.

Alshogran OY, Ocque AJ, Leblond FA, Pichette V, Nolin TD. Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine. J Chromatogr Sci. 2016 Apr;54(4):554-60. doi: 10.1093/chromsci/bmv186. Epub 2015 Dec 11. PubMed PMID: 26657732; PubMed Central PMCID: PMC4885390.

Anseeuw K, Mowry JB, Burdmann EA, Ghannoum M, Hoffman RS, Gosselin S, Lavergne V, Nolin TD. Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup. Am J Kidney Dis. 2016 Feb;67(2):187-97. doi: 10.1053/j.ajkd.2015.08.031. Epub 2015 Nov 11. Review. PubMed PMID: 26578149.

Alshogran OY, Nolin TD. Implications of Kidney Disease on Metabolic Reduction. Curr Drug Metab. 2016;17(7):663-72. Review. PubMed PMID: 27262337.

Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. 2016 Jan;27(1):305-13. doi: 10.1681/ASN.2014111063. Epub 2015 Jul 30. PubMed PMID: 26229137; PubMed Central PMCID: PMC4696571.

Mowry JB, Burdmann EA, Anseeuw K, Ayoub P, Ghannoum M, Hoffman RS, Lavergne V, Nolin TD, Gosselin S. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila). 2016;54(2):103-14. doi: 10.3109/15563650.2015.1118488. Review. PubMed PMID: 26795743.

de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, Askenazi D, Mour G, Harrell FE Jr, Pullen N, Okusa MD, Faubel S. Bridging Translation by Improving Preclinical Study Design in AKI. J Am Soc Nephrol. 2015 Dec;26(12):2905-16. doi: 10.1681/ASN.2015070832. Epub 2015 Nov 4. Review. PubMed PMID: 26538634; PubMed Central PMCID: PMC4657852.

Heung M, Faubel S, Watnick S, Cruz DN, Koyner JL, Mour G, Liu KD, Cerda J, Okusa MD, Lukaszewski M, Vijayan A. Outpatient Dialysis for Patients with AKI: A Policy Approach to Improving Care. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1868-74. doi: 10.2215/CJN.02290215. Epub 2015 Jul 28. Review. PubMed PMID: 26220818; PubMed Central PMCID: PMC4594066.

Cerdá J, Liu KD, Cruz DN, Jaber BL, Koyner JL, Heung M, Okusa MD, Faubel S. Promoting Kidney Function Recovery in Patients with AKI Requiring RRT. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1859-67. doi: 10.2215/CJN.01170215. Epub 2015 Jul 2. Review. PubMed PMID: 26138260; PubMed Central PMCID: PMC4594060.

Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, Hoffman RS, Nolin TD, Ghannoum M. Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015 Aug;43(8):1716-30. doi: 10.1097/CCM.0000000000001002. Review. PubMed PMID: 25860205.

Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, Hoffman RS. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Ann Emerg Med. 2015 Aug;66(2):165-81. doi: 10.1016/j.annemergmed.2015.03.031. Epub 2015 May 15. Review. PubMed PMID: 25986310.

Nolin TD. A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. Semin Dial. 2015 Jul-Aug;28(4):325-9. doi: 10.1111/sdi.12374. Epub 2015 Apr 8. Review. PubMed PMID: 25855244; PubMed Central PMCID: PMC4496305.

Perry Wilson F, Nolin TD, Berns JS. Drugs, Dialysis, Decisions, and Data: A Walk through the Minefield of Nephropharmacology. Semin Dial. 2015 Jul-Aug;28(4):323-4. doi: 10.1111/sdi.12390. Epub 2015 May 1. PubMed PMID: 25929704.

Walsh DR, Nolin TD, Friedman PA. Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins. Pharmacol Rev. 2015 Jul;67(3):656-80. doi: 10.1124/pr.115.010728. Review. PubMed PMID: 26092975; PubMed Central PMCID: PMC4485015.

Ghannoum M, Laliberté M, Nolin TD, MacTier R, Lavergne V, Hoffman RS, Gosselin S. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2015 Jun;53(5):454-65. doi: 10.3109/15563650.2015.1035441. Review. PubMed PMID: 25950372.

Naud J, Dumayne C, Nolin TD, Leblond FA, Pichette V. [Drug pharmacokinetics in renal failure: What's new?]. Nephrol Ther. 2015 Jun;11(3):144-51. doi: 10.1016/j.nephro.2014.12.006. Epub 2015 Apr 7. Review. PubMed PMID: 25861715.

Ocque AJ, Stubbs JR, Nolin TD. Development and validation of a simple UHPLC-MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. J Pharm Biomed Anal. 2015 May 10;109:128-35. doi: 10.1016/j.jpba.2015.02.040. Epub 2015 Feb 28. PubMed PMID: 25767908.

Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, Lavergne V, Nolin TD, Ghannoum M. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol. 2015 May 7;10(5):875-87. doi: 10.2215/CJN.10021014. Epub 2015 Jan 12. Review. PubMed PMID: 25583292; PubMed Central PMCID: PMC4422246.

Ghannoum M, Wiegand TJ, Liu KD, Calello DP, Godin M, Lavergne V, Gosselin S, Nolin TD, Hoffman RS. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2015 May;53(4):215-29. doi: 10.3109/15563650.2015.1014907. Epub 2015 Feb 26. Review. PubMed PMID: 25715736.

Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis. 2015 May;65(5):701-9. doi: 10.1053/j.ajkd.2014.11.004. PubMed PMID: 25468385; PubMed Central PMCID: PMC4414676.

Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis. 2015 Apr;65(4):574-82. doi: 10.1053/j.ajkd.2014.09.015. PubMed PMID: 25453994.

Hudson JQ, Nolin TD. Estimated GFR and cystatin C for drug dosing: moving beyond proof of concept to clinical translation?. Am J Kidney Dis. 2015 Apr;65(4):534-6. doi: 10.1053/j.ajkd.2014.11.006. PubMed PMID: 25542411.

Tortorici MA, Cutler DL, Hazra A, Nolin TD, Rowland-Yeo K, Venkatakrishnan K. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease. J Clin Pharmacol. 2015 Mar;55(3):241-50. doi: 10.1002/jcph.444. PubMed PMID: 25501531.

Roberts DM, Yates C, Megarbane B, Winchester JF, Maclaren R, Gosselin S, Nolin TD, Lavergne V, Hoffman RS, Ghannoum M. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. Crit Care Med. 2015 Feb;43(2):461-72. doi: 10.1097/CCM.0000000000000708. PubMed PMID: 25493973.

Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):159-64. doi: 10.2215/CJN.05630614. PubMed PMID: 25189923; PubMed Central PMCID: PMC4284416.

Alshogran OY, Urquhart BL, Nolin TD. Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease. Drug Metab Lett. 2015;9(2):111-8. PubMed PMID: 26282591.

Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD. Effect of experimental kidney disease on the functional expression of hepatic reductases. Drug Metab Dispos. 2015 Jan;43(1):100-6. doi: 10.1124/dmd.114.061150. PubMed PMID: 25332430.

Pai AB, Grabe DW, Eisele G, Haqqie S, Prokopienko AJ, Nolin TD, Kubotera N. Changes in plasma levels of asymmetric dimethylarginine in chronic kidney disease patients treated for 8 weeks with the vitamin D receptor agonist paricalcitol. J Res Development. 2015; 3(2):1000129. doi: 10.4172/jrd.1000129. doi: 10.4172/jrd.1000129.

SELECTED PRESENTATIONS (2015-2019)

1. “Opportunities for Improved Medication Safety in Patients with Decreased Kidney Function.” Maine Medical Center, Department of Medicine Grand Rounds, Portland, ME, September 2, 2015.

2. “Nonrenal Drug Clearance in CKD: Searching for the Path Less Traveled.” Maine Medical Center, Department of Medicine Division of Nephrology Noon Conference, Portland, ME, September 2, 2015.

3. “Drug Dose Adjustment of Non-Renally Eliminated Drugs in CKD Patients – What is the Evidence?” Keynote Lecture at 14th NephroPharmacology Meeting, Heidelberg, Germany, October 10, 2015.

4. “CRRT Pharmacokinetics: A New Chapter.” American Society of Nephrology Annual Meeting, Kidney Week 2015, San Diego, CA, November 5, 2015.

5. “Use of Kidney Function Estimates for Drug Dosing: Does One Equation Fit All?” University of Pittsburgh, School of Medicine, Department of Pathology Seminar in Laboratory Medicine, November 16, 2015.

6. “Nonrenal Drug Clearance in CKD: Searching for the Path Less Traveled.” University of Kansas Medical Center, School of Medicine, Division of Nephrology and Hypertension and the Kidney Institute Sullivan Conference, Kansas City, KS, March 4, 2016.

7. “Nonrenal Clearance in CKD.” National Kidney Foundation 2016 Spring Clinical Meeting, Boston, MA, April 27, 2016.

8. “ADME in CKD: Overview of Pharmacokinetic Alterations in Kidney Disease”. American Society of Nephrology Annual Meeting, Kidney Week 2016, Chicago, IL, November 16, 2016.

9. “Clinical Cases in CRRT and IHD.” American Society of Nephrology Annual Meeting, Kidney Week 2016, Chicago, IL, November 16, 2016.

10. “Drug Dosing in Patients Receiving RRT for AKI.” National Kidney Foundation 2017 Spring Clinical Meeting, Orlando, FL, April 21, 2017.

11. “ADME in Kidney Impairment: Searching for the Path Less Traveled.” U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, MD, May 8, 2017.

12. “Use of Kidney Function Estimates for Drug Dosing: Does One Equation Fit All?” U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, MD, May 15, 2017.

13. “Renal Replacement Therapy: Overview of PK in Intermittent and Continuous Modalities.” U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, MD, July 16, 2017.

14. “ADME in CKD: Overview of Pharmacokinetic Alterations in Kidney Disease”. American Society of Nephrology Annual Meeting, Kidney Week 2018, San Diego, CA, October 24, 2018.

15. “Pharmacokinetics and Estimation of Kidney Function in CKD: Clinical Cases”. American Society of Nephrology Annual Meeting, Kidney Week 2018, San Diego, CA, October 24, 2018.

16. “Clinical cases in RRT: Antimicrobials and Dabigatran”. American Society of Nephrology Annual Meeting, Kidney Week 2018, San Diego, CA, October 24, 2018.

17. “Medications and Drug Dosing in ESRD: Influence of Non-renal Clearance of Drugs in ESRD”. 7th Annual SUNY Downstate Dialysis Symposium: Emerging Trends in Dialysis Care, Brooklyn, NY, March 22, 2019.